Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143993 | 1.00 | CTSK (0.48) | CTSKCTSSSIRT6SIRT1ITGB3 | |
| SCHEMBL9439085 | 0.90 | CTSK (0.58) | CTSKCTSS | |
| SCHEMBL464524 | 0.88 | CTSK (0.46) | CTSKCTSS | |
| SCHEMBL17265668 | 0.87 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL31549494 | 0.87 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL15743644 | 0.85 | CTSK (0.44) | CTSKCTSS | |
| SCHEMBL445007 | 0.85 | CTSK (0.44) | CTSKCTSSSIRT6SIRT1ITGB3 | |
| SCHEMBL9538440 | 0.85 | CTSK (0.54) | CTSKCTSS | |
| SCHEMBL15821190 | 0.85 | CTSK (0.46) | CTSKCTSSSIRT6SIRT1ITGB3 | |
| SCHEMBL7256814 | 0.84 | CCKBR (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170036990-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9486538-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS GMBH (DE) | 2016-11-08 | — | — | US | disclosed |
| US-20150359906-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2015-12-17 | — | — | US | disclosed |
| US-9125820-B2 | Lipids, lipid complexes and use thereof | SILENCE THERAPEUTICS GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-20140329885-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS GMBH (DE) | 2014-11-06 | — | — | US | disclosed |
| US-20130165381-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2013-06-27 | — | — | US | disclosed |
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20110294871-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | SILENCE THERAPEUTICS AG (DE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065138-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, SGMS1 | CTSK 2810/4885CTSS 2754/4885SIRT6 1241/4885 |
| US-20110294871-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, SGMS1 | CTSK 2810/4885CTSS 2754/4885SIRT6 1241/4885 |
| US-20130165381-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | CTSK 2191/4885CTSS 2384/4885SIRT6 1422/4885 |
| US-20170036990-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | CTSK 2191/4885CTSS 2384/4885SIRT6 1422/4885 |
| US-20150359906-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | CTSK 2191/4885CTSS 2384/4885SIRT6 1422/4885 |
| US-20140329885-A1 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | MGLL, LIPA, LIPC | CTSK 2191/4885CTSS 2384/4885SIRT6 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.